Objective: Evodiamine (evo) has been shown to exert anti-inflammatory, antinociceptive and anticancer effects. In this study, we investigated the effects of evo alone and in combination with rosiglitazone (rosi) on in vitro adipocyte differentiation and in vivo obesity related to diabetes. Methods: Adipocyte differentiation was investigated in vitro using 3T3-L1 and C3H10T1/2 cells. To determine the degree of differentiation, Oil Red O staining and reverse transcription-PCR were carried out. Four groups of db/db mice were treated intraperitoneally once per day with vehicle, evo, rosi and evo þ rosi. The mice were killed after 14 days and the blood, liver and adipose tissue were analyzed. Results: The presence of evo or evo combined with rosi during adipogenic induction has been shown to inhibit adipocyte differentiation to a significant degree, particularly at the commitment and early induction stages. The evo and evo þ rosi groups of db/db mice evidenced significant reductions in body weight gain. The ratio of epididymal white adipocyte tissue weight to body weight of the evo group was also significantly reduced. It is important to note that in the evo þ rosi treatment, blood glucose levels were reduced to a degree similar to that of the rosi group, and plasma insulin levels were reduced significantly better than that of rosi group. Furthermore, hepatic lesions associated with fat and glycogen deposition were morphologically improved in the evo and evo þ rosi groups.
Introduction
Adipocytes are the principal cellular component in fat tissue, and their excessive hyperplasia or hypertrophy is recognized as fundamental processes of obesity. It is now well recognized that adipocytes function as energy storage cells and as endocrine cells. 1, 2 Therefore, increased number and size of adipocytes can induce dysregulation in circulating hormones, cytokines and substrates that affect systemic energy balance and glucose homeostasis. Adipocytes substantially increase the risk of type 2 diabetes mellitus (T2DM), cardiovascular diseases including atherosclerosis and hypertension, and other disorders. [3] [4] [5] [6] [7] Two major types of in vitro model systems have been exploited in an effort to investigate adipocyte differentiation. One such model involves the use of multipotent stem cell lines that have yet to undergo commitment to an adipocyte lineage, including the C3H10T1/2 (10T1/2) murine cell line, which is one of the most frequently used pluripotent mesenchymal cell lines. 8, 9 The cell has characteristics well suited to studies of the stem cell commitment stage. 10 The other model uses preadipocyte cell lines that have already been committed to the adipocyte lineage and can be induced to terminally differentiate into adipocytes, but not into other cell types. 3T3-L1 is the most extensively used and well-characterized preadipocyte cell line.
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The peroxisome proliferation proliferator-activated receptor (PPAR)g is known as an activator that induces insulin sensitization, and the differentiation of pluripotent cell lines into mature adipocytes. 14, 15 Rosiglitazone (rosi), a PPARg agonist, is used commonly for the treatment of T2DM patients. 16, 17 As an insulin sensitizer, rosi improves hyperglycemia and insulin resistance through an enhancement in the insulin sensitivity of adipose and muscle. 16, 18 However, the adipogenic activity of PPARg, which occurs despite efficacious antidiabetic effects, may result in undesirable side effects including obesity, edema resulting in heart failure and hepatotoxicity. [19] [20] [21] [22] Thus, it is necessary to search for effective supplements for rosi, or safer drugs that induce antidiabetic effects without adipogenic activity. Evodiamine (evo) is a quinazolinocarboline alkaloid extracted from the fruit of Wu-Zhu-Yu (Evodiae fructus; Evodia rutaecarpa Benth, Rutaceae), which has been used in traditional Chinese medicine for the treatment of gastrointestinal disorders, headache and hypertension. [23] [24] [25] It has recently been reported that evo exerts antiobesity effects through the stimulation of an extracellular signal-regulated kinase/mitogen-activated protein kinase pathway. 26 Therefore, it was interesting to assess the effects of evo alone and in combination with rosi on adipocyte differentiation in vitro and obesity related to diabetes in vivo.
Materials and methods
Cell culture and adipocyte differentiation 3T3-L1 cells (American Type Culture Collection, Rockville, MD, USA) were grown in Dulbecco's modified Eagle's medium (DMEM) including 10% bovine calf serum (BCS), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin in a humidified incubator at 5% CO 2 and 37 1C. The cells were differentiated in accordance with a well-established standard adipocyte differentiation protocol. 27 To induce adipogenesis, 3T3-L1 cells were plated (day À4) and incubated for 2 days until confluence (day À2). Then, 2-day post-confluence (day 0), the cells were stimulated to differentiate in a standard adipogenic medium (DMEM containing 10% fetal bovine serum (FBS), 0.5 mM isobutylmethylxanthine, 1 mM dexamethasone and 1 mg ml À1 insulin) for 2 days. The differentiation medium was replaced after 2 days with DMEM containing 10% FBS and 1 mg ml À1 insulin, and then exchanged with DMEM containing 10% FBS every other day. During adipocyte differentiation, 3T3-L1 cells were treated with evo at a concentration of 0.1, 1 or 10 mM from days 0 to 8 to determine the optimal concentration of evo, and treated with 1 mM evo, 1 mM rosi or 1 mM evo and 1 mM rosi (evo þ rosi) to assess the effect of evo in the presence of rosi. For the time-course study, 3T3-L1 cells were induced in the presence of 1 mM evo for various periods during adipocyte differentiation. 10T1/2 cells (American Type Culture Collection) were stimulated to differentiate through the aforementioned method, except that 10% FBS was used rather than 10% BCS in the media before induction. As recent studies have shown that bone morphogenetic protein (BMP) 4 strongly induced commitment to the adipocyte lineage, BMP4 (R&D Systems, Minneapolis, MN, USA) was used as an inducer in the commitment stage in this study. 28, 29 The cells were pretreated with DMEM containing 10% FBS with 1 mM evo, 1 mM rosi, 50 ng ml À1 BMP4, 1 mM evo and 1 mM rosi (evo þ rosi), or 1 mM evo and 50 ng ml À1 BMP4 (evo þ BMP4) during days À4 to 0. All assays were conducted in triplicate and at least three separate assays were conducted, except the experiment of BMP4 induction in which two separated assays were performed in triplicate.
Oil Red O staining
To determine the degree of differentiation and lipid accumulation, the accumulation of cytoplasmic triglycerides in the cells was detected by staining with Oil Red O (SigmaAldrich, St Louis, MO, USA). Briefly, the cells were washed in PBS, fixed with 10% buffered formalin for 60 min at 4 1C and stained for 30 min with 0.5% Oil Red O solution. The stained cells were photographed at Â 100 magnification using an Olympus CKX41 inverted microscope system (Olympus, Tokyo, Japan). After the Oil Red O retained in the cells was extracted with isopropanol, the absorbance was spectrophotometrically determined at 570 nm using an MRX II microplate reader (Dynatech Labs, Chantilly, VA, USA).
Reverse transcription-polymerase chain reaction (RT-PCR) Total RNA was isolated using Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA) in accordance with the manufacturer's instructions. Total RNA (2 mg) was converted to cDNA using an RT premix kit (Bioneer Corp., Seoul, Korea) according to the manufacturer's instructions. The cDNA population was amplified using a PCR premix kit (Intron Biotech, Seongnam, Korea) and compared with the concurrently measured b-actin expression level. For semiquantitative RT-PCR, two concentrations of the cDNA template were amplified to determine the optimal cDNA amounts. In addition, several PCR cycles were tested to determine the range in which amplification is in the exponential phase. The primers, annealing temperatures and the optimized PCR cycle number are given in Table 1 . It was conducted in triplicate and at least two separate assays were performed. 
Histological analysis
The dissected tissues were fixed in 10% neutral buffered formalin for histological analysis and embedded in paraffin. The paraffin-embedded sections were cut at a thickness of 4 mm and stained with hematoxylin and eosin. Adipocyte cell sizes were measured in seven randomly chosen microscopic areas from five independent animals using an Olympus CKX4 inverted microscope system. An average adipocyte cell size was calculated by dividing the chosen microscopic area by total adipocyte cell number in the area.
Measurements of blood glucose, serum insulin, nonesterified fatty acid and liver damage After 2 weeks of treatment, the animals were put on a 15 h fast. Blood glucose, serum insulin and nonesterified fatty acid (NEFA) levels were measured using Accu-Chek Active systems (Roche, Mannheim, Germany), an insulin immunoassay (Shibayagi, Gunma, Japan) and NEFA-HR 2 kits (Wako), respectively. Concentrations of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transminase (GPT) were determined with GOT and GPT kits (Asan Pharmaceutical, Seoul, Korea), respectively, according to the manufacturer's instructions.
Statistical analysis
The SPSS 12.0 statistical package program (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. The unpaired t-test was conducted to evaluate the statistical differences between groups. A P-value of o0.05 was considered to indicate a statistically significant difference.
Results

Evodiamine inhibits the differentiation of 3T3-L1 preadipocyte
To determine the effects of evo on the adipocyte differentiation, 3T3-L1 preadipocytes were incubated until 2-day postconfluence (day 0) and treated with evo at a concentration of 0, 0.1, 1 or 10 mM for 8 days during a standard adipogenic induction. The presence of evo was determined to significantly inhibit lipid accumulation in a dose-dependent manner through the microscopic examination of Oil Red O-stained lipid droplets and through the spectrophotometric quantification of the extracted stain (Figures 1a and b), indicating the inhibition of adipocyte differentiation in 3T3-L1. To determine the optimal concentration of evo for the treatment of 3T3-L1 without toxicity, the MTT assay was conducted after the cells were treated with evo at a concentration of 0, 0.1, 1, or 10 mM for 48 h (Figure 1c ). Evo did not evidence toxicity on cell viability at concentrations of 0.1 and 1 mM, but cell viability was decreased slightly but significantly at 10 mM ( Figure 1c) . Therefore, the optimal concentration of evo was identified as 1 mM for further studies.
To assess the effects of evo in the presence of rosi on adipoyte differentiation, we induced 3T3-L1 cells to differentiate for 8 days with 1 mM rosi treatment in the presence or absence of 1 mM evo in standard adipogenic induction media. Rosi, an agonist for PPARg, has been reported to promote adipocyte differentiation. 30, 31 Our results showed that rosi strongly induced adipocyte differentiation in 3T3-L1 compared with that of the control. When evo þ rosi were Abbreviations: aP2, fatty acid-binding protein; C/EBPa, CAAT enhancer binding protein-a; PPARg, peroxisome proliferator-activated receptor g.
Inhibitory effect of evodiamine EJ Bak et al simultaneously treated in 3T3-L1 for 8 days, evo significantly inhibited the lipid accumulation induced by rosi during adipocyte differentiation (Figures 1a and b) . The adipocyte molecular markers (PPARg, CAAT enhancer-binding protein-a (C/EBPa) and fatty-acid-binding protein (aP2)) were abundantly expressed in control and rosi-treated cells, as they were well differentiated into adipocytes (Figure 1d ). In contrast, the inhibition of lipid accumulation by evo was accompanied by a reduction in the expression level of the adipocyte molecular markers in evo alone. In addition, when evo þ rosi were treated in 3T3-L1 during adipocyte differentiation, the presence of evo was found to significantly reduce the mRNA expression level of adipocyte molecular markers, compared with that of rosi alone (Figure 1d ). The data suggest that evo exerts an inhibitory effect on the mRNA expression of adipogenic transcription factors as well as lipid accumulation in 3T3-L1, thus indicating a strong inhibition of adipocyte differentiation.
To elucidate the timing of the inhibitory effect of evo on adipocyte differentiation, we induced 3T3-L1 cells in the presence of evo for various periods. In Figure 2 , treatment with evo during days À2 to 0, 0 to 2, and 2 to 4 after induction resulted in a significant inhibition of adipocyte differentiation. In contrast, treatment of evo during days 4-6 and 6-8 evidenced no apparent inhibition. The results identified the period from day À2 to 2 as the critical time point at which evo treatment must be initiated to inhibit adipogenesis. Interestingly, the earlier treatment of evo exerted more inhibitory effect on the differentiation. Furthermore, the removal of evo at day 0 could not rescue the inhibitory effect of 3T3-L1 adipocyte differentiation, thereby indicating that the inhibitory effect of evo is irreversible.
Inhibitory effect of evodiamine at the commitment stage in C3H10T1/2 As the most profound inhibitory effect of evo occurs at the earliest treatment during differentiation in 3T3-L1 cells, we assessed the function of evo in commitment to the adipocyte lineage in multipotent 10T1/2 cells. In addition, as rosi promotes adipocyte differentiation, [32] [33] [34] we attempted to determine whether rosi can induce commitment to the adipocyte lineage in 10T1/2 cells. Proliferating 10T1/2 cells Table 1 . The error bars represent the standard error of the mean. The symbols * and ** indicate significant differences at Po0.001 and o0.05, respectively. evo, evodiamine; rosi, rosiglitazone.
Inhibitory effect of evodiamine EJ Bak et al were pretreated with 1 mM evo, 1 mM rosi, evo þ rosi, 50 ng ml À1 BMP4 or evo þ BMP4 for days À4 to 0, followed by 8 days of the standard differentiation induction. Rosi significantly induced commitment to the adipocyte lineage ( Figure 3 ). BMP4 strongly induced commitment to the adipocyte lineage (Figure 3) , consistent with the results of earlier studies. 28, 29, 35 Treatment with rosi or BMP4
for commitment accelerated adipocyte differentiation in 10T1/2, as it required only 8 days to generate mature lipidladen adipocytes rather than the differentiation of control cells, which remained quite weak after 8 days.
In the pretreatment of evo þ rosi during commitment, adipocyte differentiation was inhibited significantly compared with that of rosi alone (Figure 3) , thereby indicating Inhibitory effect of evodiamine EJ Bak et al that evo inhibits rosi-triggered commitment to the adipocyte lineage. In addition, in the pretreatment of evo þ BMP4, the strong induction of adipocyte differentiation by BMP4-triggered commitment was inhibited almost completely by evo. These data indicate that evo exerts a profound inhibitory effect on the commitment stage of pluripotent mesenchymal cells to the adipocyte lineage, in addition to inhibiting the early induction stage of adipocyte differentiation.
Evodiamine prevents body weight gain in db/db mice To examine the gross body changes of db/db mice after treatment with evo, rosi or evo þ rosi, we measured the body weights and food intake of the mice every day during the experimental period. Body weight gains were significantly less in the evo and evo þ rosi groups than in the control and rosi groups (Figure 4a ). In the evo group and the evo þ rosi group, body weights were increased by 2 ± 0.57 g (Po0.05 vs control group and Po0.001 vs rosi group) and 1.6±0.43 g (Po0.05 vs control group and Po0.001 vs rosi group), respectively, whereas those in the control group and the rosi group were elevated markedly by 4.75±0.66 and 6±0.2 g, respectively. Food intake among all db/db mice groups was not found to differ significantly (Figure 4b ), thereby indicating that the treated mice might have normal appetites and that the effects observed in the in vivo study were not attributable to food intake.
Effect of evodiamine on white adipose tissues and liver in db/db mice To examine the internal organ changes of db/db mice by treatment with evo, rosi or evo þ rosi, the animals were weighed and killed at the end of treatment. EWAT, PWAT, liver, kidney and heart were dissected and weighed, and the tissue weight/body weight ratios were calculated ( Table 2 ). The ratios of EWAT and PWAT in the rosi group were the highest and the liver ratio in the rosi group was the second highest after that of the control group ( Table 2 ). The ratios of EWAT (5.0 ± 0.5, Po0.05) and PWAT (2.4 ± 0.2, Po0.05) in the evo group were reduced significantly compared with those of the rosi group (EWAT, 5.7 ± 0.2; PWAT, 3.1 ± 0.5).
In addition, this ratio of EWAT in the evo þ rosi group was reduced significantly compared with that of the rosi group (5.3 ± 0.3, Po0.05). The liver ratios were also significantly reduced in the evo group (5.2 ± 0.7, Po0.05) and rosi group (5.5±0.3, Po0.05) compared with those of the control group (6.1±0.3), and furthermore the ratio in the evo þ rosi group (5.0 ± 0.3, Po0.001) was reduced more significantly than in the control group. The ratios of the heart and kidney Inhibitory effect of evodiamine EJ Bak et al did not differ significantly among the groups (data not shown).
The reduction of adipocyte size in the EWAT and PWAT of the evo and evo þ rosi groups was observed on histopathological analysis (Figures 5a and b) . Adipocyte size in both WATs was quantified by measuring randomly chosen microscopic areas and it was markedly decreased in the evo and evo þ rosi groups compared with control and rosi groups (Po0.01; Figure 5c ). The disappearance of lipid droplets and glycogen deposition was observed in the livers of the evo and evo þ rosi groups whereas accumulation of large lipid droplets and severe glycogen deposition was observed in those of the control and rosi groups ( Figure 6 ). In addition, enlarged hepatocytes in the control and rosi groups were normalized in the presence of evo.
Effect of evodiamine on blood glucose, serum insulin, nonesterified fatty acid and liver damage indexes To determine whether evo exerts antidiabetic effects in db/ db mice, we measured the blood glucose, serum insulin and NEFA levels after 15 h of fasting. The blood glucose level was reduced, but not significantly, in the evo group (326.6± 65.57) compared with the control group (357.75 ± 32.45) (Figure 7a) . The blood glucose levels of the rosi and evo þ rosi groups were reduced significantly, to 247.5±54.2 and 280± 57.07, respectively (Po0.05 vs control group). The serum insulin level of the evo group was reduced significantly, to 4.83±1.3 (Po0.05 vs control group), and the level in the rosi group was reduced but not significantly, to 4.9±1.4 compared with that of the control group (7.24 ± 1.3). Interestingly, the level noted in the evo þ rosi group was reduced to 2.7±0.7 (Po0.05), a more significant reduction than was noted in the rosi group; this reflects an addictive effect of evo and rosi (Figure 7b ). The NEFA levels of the evo group (1.37±0.21, Po0.001) and the rosi group (1.41±0.3, Po0.01) were significantly reduced compared with that of the control group (2.55 ± 0.36) (Figure 7c ). Like the pattern of serum insulin level, the NEFA level of the evo þ rosi group (1.01 ± 0.24) was reduced more than the levels measured in the other groups. In addition, the liver damage indexes, GPT and GOT, were measured to determine the effect of evo and rosi on liver toxicity, and were as follows: GPT (IU l À1 ); control 19.95 ± 1.86, rosi 18.28 ± 2.50, evo 18.23 ± 2.94 and evo þ rosi 17.65 ± 3.04 and GOT (IU l À1 ); control 20.86 ± 2.28, rosi 18.91±3.01, evo 21.05±0.78 and evo þ rosi 19.95 ± 3.32. The indexes showed that there was no significant difference among groups and therefore evo or rosi did not show toxicity on liver in this study.
Discussion
As T2DM is a chronic and progressive disorder, an extra preconscious step in pharmacotheraphy will be necessary to improve drug-related side effects over a long time period. Therefore, the majority of patients may require a combination of drugs. Currently, rosi exerts prominent antidiabetic effects by increasing insulin sensitivity and improving glycemic condition in T2DM patients, but the side effects of rosi, including liver and heart failure, and body weight increases, have been reported. 36 Evo showed an antiobesity effect in C57BL/6J mice fed on 60% high fat diets over 2 months in our preliminary study and recent report. 26, 37 In an effort to find a therapeutic drug that effectively minimizes the potential side effects of rosi while preserving the insulin sensitivity effects, we evaluated the effects of evo on adipogenesis and T2DM in the in vitro and in vivo assays conducted herein.
In the in vitro experiments, evo treatment administered during the entire adipogenic induction period was shown to inhibit lipid accumulation and the level of adipocyte marker expression. Similar phenomena were observed in cases in which rosi was administered simultaneously with evo. The time-course study of evo treatment revealed a strict temporal requirement for its effects on adipocyte differentiation: Evo exerts an inhibitory effect on adipocyte differentiation in the early induction stage, but no effect in later stages. These results indicate that evo regulates the adipogenic process and may perform a critical negative role in adipocyte differentiation.
We evaluated the role of evo in commitment before the induction period using multipotent 10T1/2 cells, which have yet to undergo commitment to the adipocyte lineage. BMPs are members of the transforming growth factor-b superfamily. BMPs were originally identified as peptides that induce the formation of the bone, 38 and now they are known to induce pleiotropic developments. 39, 40 Among the BMPs, BMP4 can induce the commitment stage of 10T1/2 pluripotent stem cells to the adipocyte lineage by smad signaling pathway. 10, 28, 41 In this study, as expected, BMP4
profoundly induced the adipocyte commitment stage of 10T1/2, and for the first time we report that rosi also induced the commitment stage at a relatively lower level than the BMP4 induction level. These commitment inductions triggered by rosi or BMP4 were inhibited by evo treatment. These results indicate that evo exerts a profound inhibitory effect in the commitment stage, and in the early induction stage of adipogenic differentiation.
On the basis of current understanding of adipocyte differentiation, the increased fat mass in obesity 24, 42, 43 results from an increase in total adipocyte number (hyperplasia) as well as an increase in individual adipocyte cell size (hypertrophy). 44, 45 Hyperplasia appears primarily in the commitment stages in adipose tissue development and is caused by the proliferation and differentiation of mesenchymal stem cells into preadipocytes. 46, 47 Hypertrophy occurs as the result of excessive accumulation of triglycerides during the process of differentiation from preadipocytes to mature adipocytes. 48 Therefore, evo may reduce hyperplasia and hypertrophy in fat tissue through an induced inhibition of both adipocyte number and size.
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Earlier studies using db/db mice showed that body weight increased significantly as the result of rosi treatment at a dosage of 10 mg kg À1 per day, 49, 50 thereby indicating that rosi exerts an undesirable effect on body weight. According to the results of our in vivo study, evo evidenced an apparent antiobesity effect on body weight and the ratios of EWAT and liver weight/body weight in both cases of the absence and presence of rosi. These results suggest that evo may have a beneficial influence on T2DM, such as the inhibition of body weight gains, and also that evo may overcome the undesirable effects of rosi. It is worth noting another concern that the elimination of the rosi-undesirable effect, body weight gain, might not be an effective approach against diabetes as the increase in the adipose tissue containing small adipocytes at least partially accounts for the rosi-desirable effect and the insulin-sensitizing ability. Therefore, it was interesting to investigate whether evo can eliminate the rosi-undesirable effect by affecting the rosi-desirable effect.
In the EWAT of the evo and evo þ rosi groups, the adipocyte size was reduced and the weight ratios were also reduced. Therefore, the reduction of adipocyte size in the EWAT may result in a reduction in the EWAT weight ratios. In the livers of the evo group mice, the ratio was decreased and lipid droplets and glycogen deposition were improved compared with the control and rosi groups. Furthermore, these effects of evo on the EWAT and the liver were enhanced Figure 6 Histological analysis of livers of db/db mice after control, evo, rosi or evo þ rosi treatments for 14 days. Microscopic pictures of liver were obtained at magnifications of Â 100. evo, evodiamine; rosi, rosiglitazone. A white arrow indicates a fat droplet and a black arrow indicates glycogen deposition. Figure 7 Effects of evo on blood glucose, serum insulin and NEFA levels in db/db mice after 15 h of fasting. (a) Blood glucose levels were determined using AccuChek Active systems. (b) Serum glucose levels were determined using an enzyme-linked immunosorbent assay (ELISA) kit. (c) NEFA levels were determined with a commercial NEFA kit. The symbols * , ** and *** indicate significant differences at Po0.05, o0.01 and o0.001, respectively. evo, evodiamine; rosi, rosiglitazone; NEFA, nonesterified fatty acid.
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EJ Bak et al substantially in the evo þ rosi treatment group, thus suggesting that evo and rosi exert synergistic effects. In this study, the blood-glucose-lowering effect of rosi was preserved in the evo þ rosi group, even though blood glucose levels were not improved by 2 weeks of treatment with evo alone in the db/db mice. In earlier reports, the effects of evo on glucose levels were associated with diverse results. When evo was administered for 7 weeks, blood glucose levels were reduced in mice with diet-induced obesity, 26 whereas the serum glucose levels remained unchanged in the SpragueDawley rats treated for 3 weeks with evo. 37 This controversy may be attributed to the different genetic backgrounds of animals, the duration of drug administration and fasting or nonfasting effects. As to serum biochemistry, the evo group evidenced significant improvements in serum insulin and NEFA levels compared to those of the control group. Furthermore, serum insulin and NEFA levels in the evo þ rosi group were improved by approximately 45 and 30%, respectively. This is a result superior to those observed in the evo or rosi groups. The improvement of serum insulin and NEFA levels is another important beneficial effect of evo on T2DM.
In conclusion, evo exerts an inhibitory effect on adipocyte differentiation at the commitment and early induction stages, and this inhibitory effect may be responsible for the observed antiobesity effects, and furthermore may account for improved insulin resistance observed in the in vivo experiments. The inhibitory effects of evo were preserved during treatment with a combination of rosi treatment in vitro and in vivo, thereby indicating that evo inhibits the undesirable effects of rosi, including increases in adiposity and hepatotoxicity, without abrogation of the desirable blood-glucose-lowering effects. Therefore, the results of this study warrant further investigations into the possible efficacy of evo as a therapeutic agent for the amelioration of diabetic conditions.
